Max Keller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6269571/publications.pdf

Version: 2024-02-01

44	881	471509	526287
papers	citations	17	27
		h-index	g-index

45	45	45	708
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor. Nature, 2018, 556, 520-524.	27.8	100
2	Acylguanidines as Bioisosteres of Guanidines: N^G-Acylated Imidazolylpropylguanidines, a New Class of Histamine H₂ Receptor Agonists. Journal of Medicinal Chemistry, 2008, 51, 7193-7204.	6.4	69
3	Guanidineâ^'Acylguanidine Bioisosteric Approach in the Design of Radioligands: Synthesis of a Tritium-Labeled N^G-Propionylargininamide ([³H]-UR-MK114) as a Highly Potent and Selective Neuropeptide Y Y₁ Receptor Antagonist. Journal of Medicinal Chemistry, 2008, 51, 8168-8172.	6.4	50
4	Synthesis and Characterization of the First Fluorescent Nonpeptide NPY Y₁ Receptor Antagonist. ChemBioChem, 2007, 8, 1981-1988.	2.6	49
5	Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools. Bioorganic and Medicinal Chemistry, 2011, 19, 2859-2878.	3.0	42
6	Initial Characterization of Transgenic Mice Overexpressing Human Histamine H₂Receptors. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 129-141.	2.5	40
7	Mimicking of Arginine by Functionalized N[‰]-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples. Journal of Medicinal Chemistry, 2016, 59, 1925-1945.	6.4	34
8	High Affinity Agonists of the Neuropeptide Y (NPY) Y₄ Receptor Derived from the C-Terminal Pentapeptide of Human Pancreatic Polypeptide (hPP): Synthesis, Stereochemical Discrimination, and Radiolabeling. Journal of Medicinal Chemistry, 2016, 59, 6045-6058.	6.4	25
9	Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M₂ Muscarinic Acetylcholine Receptor. Journal of Medicinal Chemistry, 2017, 60, 3314-3334.	6.4	25
10	Highly Potent, Stable, and Selective Dimeric Hetarylpropylguanidine-Type Histamine H₂ Receptor Agonists. ACS Omega, 2018, 3, 2865-2882.	3.5	24
11	Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists. Bioorganic and Medicinal Chemistry, 2008, 16, 9858-9866.	3.0	23
12	Dimeric carbamoylguanidine-type histamine H2 receptor ligands: A new class of potent and selective agonists. Bioorganic and Medicinal Chemistry, 2015, 23, 3957-3969.	3.0	23
13	N[‰]-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y₁ Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([³H]UR-MK299) with Extended Residence Time. Journal of Medicinal Chemistry, 2015, 58, 8834-8849.	6.4	23
14	Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors. Science Advances, 2022, 8, eabm1232.	10.3	22
15	The Neuropeptide Y Y1 Receptor: A Diagnostic Marker? Expression in MCF-7 Breast Cancer Cells Is Down-Regulated by Antiestrogens In Vitro and in Xenografts. PLoS ONE, 2012, 7, e51032.	2.5	20
16	Dimeric argininamide-type neuropeptide Y receptor antagonists: Chiral discrimination between Y1 and Y4 receptors. Bioorganic and Medicinal Chemistry, 2013, 21, 6303-6322.	3.0	20
17	Bivalent Argininamideâ€Type Neuropeptideâ€...Y Y₁ Antagonists Do Not Support the Hypothesis of Receptor Dimerisation. ChemMedChem, 2009, 4, 1733-1745.	3.2	19
18	Application of the Guanidineâ€“Acylguanidine Bioisosteric Approach to Argininamideâ€Type NPY Y₂ Receptor Antagonists. ChemMedChem, 2011, 6, 1727-1738.	3.2	19

#	Article	IF	Citations
19	Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M₂R Affinity and Selectivity. ACS Omega, 2017, 2, 6741-6754.	3.5	19
20	Fluorescence Labeling of Neurotensin(8â€“13) via Arginine Residues Gives Molecular Tools with High Receptor Affinity. ACS Medicinal Chemistry Letters, 2020, 11, 16-22.	2.8	17
21	[³H]URâ€MK136: A Highly Potent and Selective Radioligand for Neuropeptide Y Y₁ Receptors. ChemMedChem, 2011, 6, 1566-1571.	3.2	16
22	M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of chemical homo-dimerization on orthosteric (and allosteric?) binding. Bioorganic and Medicinal Chemistry, 2015, 23, 3970-3990.	3.0	15
23	Modifications at Arg and Ile Give Neurotensin(8â€“13) Derivatives with High Stability and Retained NTS₁ Receptor Affinity. ACS Medicinal Chemistry Letters, 2019, 10, 960-965.	2.8	14
24	Conjugation of Short Peptides to Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Determines M₂R Selectivity. Journal of Medicinal Chemistry, 2019, 62, 5358-5369.	6.4	13
25	Red-Emitting Dibenzodiazepinone Derivatives as Fluorescent Dualsteric Probes for the Muscarinic Acetylcholine M2 Receptor. Journal of Medicinal Chemistry, 2020, 63, 4133-4154.	6.4	13
26	Photochromic peptidic NPY Y₄ receptor ligands. Organic and Biomolecular Chemistry, 2019, 17, 2467-2478.	2.8	13
27	Fluorescence- and Radiolabeling of [Lys⁴,Nle^{17,30}]hPP Yields Molecular Tools for the NPY Y₄ Receptor. Bioconjugate Chemistry, 2017, 28, 1291-1304.	3.6	12
28	Prototypic ¹⁸F-Labeled Argininamide-Type Neuropeptide Y Y₁R Antagonists as Tracers for PET Imaging of Mammary Carcinoma. ACS Medicinal Chemistry Letters, 2017, 8, 304-309.	2.8	11
29	In Search of NPY Y₄R Antagonists: Incorporation of Carbamoylated Arginine, Aza-Amino Acids, or <scp>d</scp>-Amino Acids into Oligopeptides Derived from the C-Termini of the Endogenous Agonists. ACS Omega, 2017, 2, 3616-3631.	3.5	11
30	Oligopeptides as Neuropeptide Y Y₄ Receptor Ligands: Identification of a High-Affinity Tetrapeptide Agonist and a Hexapeptide Antagonist. Journal of Medicinal Chemistry, 2020, 63, 8198-8215.	6.4	11
31	N-Terminus to Arginine Side-Chain Cyclization of Linear Peptidic Neuropeptide Y Y₄ Receptor Ligands Results in Picomolar Binding Constants. Journal of Medicinal Chemistry, 2021, 64, 16746-16769.	6.4	11
32	[³H]URâ€PLN196: A Selective Nonpeptide Radioligand and Insurmountable Antagonist for the Neuropeptideâ€…Y Y₂â€…Receptor. ChemMedChem, 2013, 8, 587-593.	3.2	10
33	Differently fluorescence-labelled dibenzodiazepinone-type muscarinic acetylcholine receptor ligands with high M₂R affinity. RSC Medicinal Chemistry, 2020, 11, 823-832.	3.9	10
34	Structure-Based Design of High-Affinity Fluorescent Probes for the Neuropeptide Y Y₁ Receptor. Journal of Medicinal Chemistry, 2022, 65, 4832-4853.	6.4	10
35	18F-labelled triazolyl-linked argininamides targeting the neuropeptide Y Y1R for PET imaging of mammary carcinoma. Scientific Reports, 2019, 9, 12990.	3.3	9
36	BRET- and fluorescence anisotropy-based assays for real-time monitoring of ligand binding to M2 muscarinic acetylcholine receptors. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118930.	4.1	8

#	Article	IF	Citations
37	Live-cell microscopy or fluorescence anisotropy with budded baculovirusesâ€"which way to go with measuring ligand binding to M ₄ muscarinic receptors?. Open Biology, 2022, 12, .	3.6	6
38	Toward Labeled Argininamideâ€Type NPY Y₁ Receptor Antagonists: Identification of a Favorable Propionylation Site in BIBO3304. Archiv Der Pharmazie, 2015, 348, 390-398.	4.1	5
39	Fluorescent H₂ Receptor Squaramide-Type Antagonists: Synthesis, Characterization, and Applications. ACS Medicinal Chemistry Letters, 2020, 11, 1521-1528.	2.8	5
40	Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity. European Journal of Medicinal Chemistry, 2021, 213, 113159.	5.5	5
41	An Alkyne-functionalized Arginine for Solid-Phase Synthesis Enabling â€œBioorthogonalâ€•Peptide Conjugation. ACS Medicinal Chemistry Letters, 2020, 11, 334-339.	2.8	4
42	Two dibenzodiazepinone molecules with dissimilar dimeric associations and apparent different tautomeric forms. Acta Crystallographica Section C: Crystal Structure Communications, 2012, 68, o240-o246.	0.4	3
43	Argininamide-type neuropeptide Y Y1 receptor antagonists: the nature of NÏ‰-carbamoyl substituents determines Y1R binding mode and affinity. RSC Medicinal Chemistry, 2020, 11, 274-282.	3.9	0
44	Ga-68 labeling of stable neurotensin(8-13) analogs via carbamoylated arginine residues gives NTS 1 R PET ligands with promising in vitro profile. , 2020, 59, .		0